3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Gastrointestinal
5
Tumor-Agnostic
3
Thoracic
2
Sarcoma
1
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
NET
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Breast Neoplasms
111
Triple Negative Breast Neoplasms
25
Lung Neoplasms
8
Pancreatic Neoplasms
6
Neoplasm Metastasis
6
Colonic Neoplasms
6
Ovarian Neoplasms
5
Neoplasms
5
Melanoma
5
Colorectal Neoplasms
5
Stomach Neoplasms
4
Head and Neck Neoplasms
4
Esophageal Neoplasms
4
Sarcoma
3
Liver Neoplasms
3
Kidney Neoplasms
3
Cholangiocarcinoma
3
Uterine Cervical Neoplasms
2
Multiple Myeloma
2
Motor Activity
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Laryngeal Neoplasms
2
Gastrointestinal Neoplasms
2
Fatigue
2
Fallopian Tube Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Brain Neoplasms
2
Bile Duct Neoplasms
2
Interventions
spartalizumab
2
pembrolizumab
2
trastuzumab deruxtecan
1
trametinib
1
siremadlin
1
sargramostim
1
resiquimod
1
poly ICLC
1
pegfilgrastim
1
nazartinib
1
liposomal doxorubicin
1
lenvatinib
1
eribulin
1
enzalutamide
1
canakinumab
1
Vaccines
1
TKM-080301
1
Quality of Life
1
Prednisone
1
Prednisolone
1
Patient Reported Outcome Measures
1
Panobinostat
1
Molecular Diagnostic Techniques
1
MORAb-202
1
LCL161
1
Ipilimumab
1
Immunotherapy
1
Imatinib Mesylate
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Everolimus
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma
×
Drug Therapy
×
Breast
×
Clear all
NCT04028479
2024-12-18
ROOT
Taproot Health
Completed
167 enrolled